The cure rate for [diffuse midline glioma] is less than 1%, and the median overall survival is nine to 11 months,” said Dr.

Bernstein SocGen Group has revised its price target for Merck (NYSE:MRK) shares, bringing it down to $95 from the previous $110 while maintaining a Market Perform rating. Analyst Courtney Breen cited ...

Merck (MRK) is a leading global healthcare company recognized for its groundbreaking pharmaceutical products and vaccines.

They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...